T-Therapeutics secures $133 million Series B to advance bispecific cancer and autoimmune drugs
T-Therapeutics, a UK-based biotech focused on T-cell engager technology, announced a $133 million Series B financing.
The capital will be used to generate proof-of-concept data for its lead bispecific antibody TTX-008, aimed at an unspecified pan-tumor driver, and for TTX-018, intended for autoimmune diseases. Neither candidate has entered human trials.
CEO Theodora Harold said the funding marks a transition toward a clinical-stage company and highlighted the platform's ability to produce fully human T-cell receptors with high affinity and specificity, which the firm believes could enable blockbuster-level, pan-indication therapies.
The company disclosed limited details about the drug targets or development timelines.
This writeup was produced by pharmadog from original reporting by BioPharma Dive.
Original headline: “T-Therapeutics reloads with a $133M megaround for bispecifics”
read at BioPharma Dive ↗
comments(0)
5-min edit window · permanent after that